Overview

Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic prostate cancer
Phase:
Phase 2
Details
Lead Sponsor:
Kantonsspital Graubünden
Collaborator:
Janssen-Cilag Ltd.
Treatments:
Metformin